Formycon Reports Significant Financial Growth in H1 2026

Formycon AG has reported substantial improvements in its financial results for the first half of 2026. The company's revenue increased significantly to EUR 25.8 million from EUR 9.0 million in the previous year. This growth was driven by milestone payments from commercialization and higher royalty income from marketed biosimilars.

A pivotal achievement was the completion of the FYB206 clinical development, bolstering Formycon’s stance in the pembrolizumab biosimilar market. Another milestone was the EU launch of FYB203, enhancing the commercial portfolio.

Strategic partnerships, like the one with OneSource, have strengthened Formycon’s manufacturing capabilities. The company's strategy, FYB4Growth, focuses on sustainable development and maintaining a competitive edge in the biosimilars market.

Formycon anticipates further revenue growth in the second half of 2026, expecting key contributions from FYB206 and other biosimilars. The company maintains its financial guidance for the year and continues to monitor market performance closely.